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ABSTRACT:  
Audience: This simulation was developed to educate emergency medicine residents on the diagnosis and 
management of high-altitude pulmonary edema (HAPE). This case is also appropriate for senior medical 
students and advanced practice providers. The principles of crisis resource management, teamwork, and 
communication are incorporated into the case. 
 
Introduction: High altitude pulmonary edema may present similarly to pneumonia with nonspecific 
symptoms, including decreased exercise tolerance, cough, dyspnea with exertion, and fever. Symptoms more 
specific to HAPE include dyspnea at rest, tachypnea, history of rapid ascent to high altitude, a lowlander 
patient exposed to high-altitude, or a highlander patient on re-entrance to high altitude after lowland stay. 
Laboratory and imaging workup may include infiltrates on chest x-ray and leukocytosis.1,2 Of the various 
forms of altitude sickness, HAPE has the highest fatality rate, estimated at 50% in travellers to the Himalayas 
who are unable to descend.1 Providers should inquire as to the current elevation of their facility, the patient’s 
recent altitude gain, and the rate of ascent.  Treatment priorities include oxygen and immediate descent, as 
well as supplemental treatment with nifedipine and phosphodiesterase (PDE) inhibitors such as sildenafil or 
tadalafil. 
 
Educational Objectives: At the conclusion of the simulation session, learners will be able to:  
1. obtain a thorough history relevant to altitude illnesses  
2. develop a differential for dyspnea in a patient with environmental exposures 
3. discuss prophylaxis and management of HAPE 
4. discuss appropriate disposition of the patient including descent and subsequent appropriate level of 
care 
 
Educational Methods: This session was conducted using high-fidelity simulation followed by a debriefing 
session and lecture on the diagnosis and management of HAPE. Debriefing methods may be left to the 
discretion of participants, but the authors have utilized advocacy-inquiry techniques. This technique includes 
an observation statement, a statement describing the framework of the observer, and an invitation to review 
further to explore the participants’ frames. An example of this advocacy-inquiry is as follows: “I heard Sam 
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suggest to the team that acetazolamide be given, but then I didn’t hear any follow-up discussion. 
Acetazolamide is often utilized for acute mountain illness prophylaxis or treatment. I wasn’t sure if the team 
did not hear his suggestion or disagreed with the treatment plan. Tell me more.” This scenario was designed 
as a simulation, but it could be adapted as an oral boards case.  
 
Research Methods: Our residents were provided with a survey at the completion of the simulation and 
debriefing to rate different aspects of the simulation, as well as to provide qualitative feedback. 
 
Results: Participants expressed positive feedback, with comments focused on appreciating the review of the 
presentation, diagnosis, and treatment of altitude illness. The emergency medicine residents surveyed 
currently practice in a low altitude setting and were appreciative to simulate a scenario to which they might 
otherwise not get exposure during their residency. Our simulation center’s feedback form is based on the 
Center of Medical Simulation’s Debriefing Assessment for Simulation in Healthcare (DASH) Student Version 
Short Form. This session received all 6 or 7 scores (consistently effective/very good or extremely 
effective/outstanding) other than a 5 for setting the stage, a 4 for maintaining an engaging context for 
learning, and two 5s for structured debriefing. 
 
Discussion: This was an effective method to review high altitude illness with learners that may otherwise get 
limited exposure to such clinical cases during residency. Learners had a broad range of differential diagnoses 
and demonstrated variable levels of knowledge related to the diagnosis and treatment of high-altitude 
illness. We used visual stimuli and a reminder from our nurse to reinforce for the learners that the case was 
taking place at a critical access emergency room at 11,000 feet of elevation. 
 
Topics: Medical simulation, high altitude pulmonary edema, high altitude cerebral edema, altitude sickness, 
emergency medicine, wilderness medicine. 
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Linked objectives and methods:  
High altitude pulmonary edema is an uncommon ED 
presentation, and many of the symptoms are consistent with 
much more common diagnoses such as cardiogenic pulmonary 
edema or pneumonia. This scenario enforces the importance of 
obtaining a thorough history including ascent profile, baseline 
altitude, and maintaining a high clinical suspicion for altitude 
illness in the appropriate setting (objective 1). Learners will be 
required to develop a differential for dyspnea in a patient with 
environmental exposures (objective 2). Learners will need to 
identify the appropriate management of HAPE, as well as 
prophylaxis (objective 3), including appropriate disposition, 
including descent to lower altitude and inpatient level of care 
(objective 4).This simulation scenario allows learners to 
reinforce their HAPE management skills in a psychologically safe 
learning environment, and then receive formative feedback on 
their performance.  
 
Recommended pre-reading for instructor:  
We recommend that instructors review the Wilderness Medical 
Society Practice Guidelines for the Prevention and Treatment of 
Acute Altitude Illness: 2019 Update.7 Other suggested readings 
include materials listed below under the 
“References/suggestions for further reading” section. 
 
Results and tips for successful implementation:  
This simulation was written to be performed as a high-fidelity 
simulation scenario, but also may be used as a mock oral board 
case.  
 
The case was written for emergency medicine residents and 
may be presented in an outdoor setting or simulation lab. We 
conducted this simulation with emergency medicine residents 
during the 2019-2020 academic year. Despite having a sign on 
the door that informed participants that they were 
moonlighting at an ED in the Rocky Mountains for this scenario, 
some groups needed further reinforcement to remind them 
that they are not in their usual ED location. Once participants 
realized they were at a high-altitude location, their differentials 
then immediately expanded to include altitude-related 
illnesses. For this reason, we did not have nursing consistently 
remind them that they were in a high-altitude critical access ED 
in order to minimize diagnostic anchoring.  
 
During debriefing, participants expressed overall positive 
feedback including reviewing the spectrum of altitude related 
illnesses with approaches for both prophylaxis and treatment. 
The emergency medicine residents currently practice in a low-
altitude setting and appreciated the simulation of a scenario to 
which they might not otherwise be exposed in their clinical 
residency training.  
 
Our simulation center’s feedback form is based on the Center of 
Medical Simulation’s Debriefing Assessment for Simulation in 
Healthcare (DASH) Student Version Short Form with the 
inclusion of required qualitative feedback if an element was 
scored less than a 6 or 7. This session received all 6 or 7 scores 
(consistently effective/very good or extremely 
effective/outstanding) other than a 5 for setting the stage, a 4 
for maintaining an engaging context for learning, and two 5s for 
structured debriefing . Our form also includes an area for 
general feedback about the case at the end. Qualitative 
comments for the “setting the stage” category included, 
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Learner Audience:  
Medical students, interns, junior residents, senior residents
  
Time Required for Implementation:  
Instructor Preparation: 30 minutes 
Time for case: 20 minutes 
Time for debriefing: 40 minutes 
 
Recommended Number of Learners per Instructor: 
4 
 
Topics: 
Medical simulation, high altitude pulmonary edema, high 
altitude cerebral edema, altitude sickness, emergency 
medicine, wilderness medicine. 
 
Objectives:  
By the end of this simulation session, the learner will be able 
to: 
1. Obtain a thorough history, including current 
altitude, rate of ascent, peak altitude, patient’s 
baseline altitude, and assessment for other causes 
of dyspnea and altered mental status 
2. Develop a differential for dyspnea in a patient with 
significant environmental exposures 
3. Discuss prophylaxis and management of HAPE  
4. Discuss appropriate disposition of the patient in 
both the field and in the high-altitude ED or clinic, 
including descent and subsequent appropriate level 
of care 
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“Would have preferred more info from nurse about physically 
where we are and what type of hospital and what information 
we had?” reflecting the earlier sentiment that many residents 
needed further prompting that they were at a high-altitude ED 
instead of their typical practice location. The qualitative 
comment for the 4 score for the maintaining an engaging 
context for learning was, “When we were struggling in 
simulation it would have been nice to have a nudge or a clue 
rather than just more silence.” Our typical practice is to allow 
the participants to work through their differentials and give 
them opportunity to revisit their decision-making processes 
without prompting unless they are unable to move forward. All 
other scores in this area were 6s and 7s. Qualitative comments 
for debriefing were for both 5 scores and included, “Went well 
overall, I just didn’t know a whole lot about the topic,” and 
“great case,” so the authors wonder if one of those 5 scores 
was more reflective of the learner’s baseline knowledge about 
HAPE, rather than how the debriefing was structured or 
conducted.  
 
References/suggestions for further reading:  
1. Bartsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O. 
Prevention of high-altitude pulmonary edema by 
nifedipine. N Engl J Med. 1992;325(18):1284-1289. doi: 
10.1056/NEJM199110313251805. 
2. Paralikar S. High altitude pulmonary edema-clinical 
features, pathophysiology, prevention and 
treatment. Indian J Occup Environ Med. 2012;16(2):59. doi: 
10.4103/0019-5278.107066. 
3. Richalet J, Gratadour P, Robach P, et al. Sildenafil inhibits 
altitude-induced hypoxemia and pulmonary 
hypertension. Am J Respir Crit Care Med. 2005;171(3):275-
281. doi: 10.1164/rccm.200406-804OC. 
4. Maggiorini M, Brunner-La Rocca HP, Peth S, et al. Both 
tadalafil and dexamethasone may reduce the incidence of 
high-altitude pulmonary edema: a randomized trial. Ann 
Intern Med. 2006; 145:497-506. doi: 10.7326/0003-4819-
145-7-200610030-00007. 
5. Brown J, Grocott M. Humans at altitude: physiology and 
pathophysiology. CEAPCCP. 2013;13(1):17-22. 
6. Bidinger J, Bowman J, Bisschops L, et al. Altitude medicine. 
In: Della-Giustina D, Ingebretsen R, eds. Advanced 
Wilderness Life Support, 9th Edition. Adventure Med, LLC; 
2016:61-70. 
7. Luks AM, Auerbach PS, Freer L, et al. Wilderness Medical 
Society consensus guidelines for the prevention and 
treatment of acute altitude illness: 2019 update. 
Wilderness Environ Med. 2019;30(4S): S3-S18. doi: 
10.1016/j.wem.2019.04.006. 
8. Hackett PH, Shlim DR.  High-Altitude Travel & Altitude 
Illness. CDC. 
https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-
travel-consultation/altitude-illness. Published 2018. 
Accessed November 15, 2018. 
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Case Title: High Altitude Pulmonary Edema 
 
Case Description & Diagnosis (short synopsis): Patient is a 27-year-old healthy female hiker 
who presents from the wilderness with dyspnea. Per EMS, the patient was backpacking in the 
Rocky Mountains with friends. Throughout the day, she was having increasing trouble keeping 
up and appeared to be mildly short of breath. The shortness of breath worsened and did not 
resolve with rest, despite more frequent breaks to rest and a slower pace. When she did not 
improve while resting in camp, her friends hiked down to town to call for rescue. She was 
evacuated in a litter by search and rescue. She is currently too dyspneic to speak. Participants 
should obtain an oxygen saturation, temperature, electrocardiogram (ECG), arterial blood gas 
(ABG), chest x-ray (CXR), and blood work. Diagnostics will reveal low oxygen saturation, low 
partial pressure of oxygen (PaO2), mild leukocytosis, and CXR findings consistent with 
pulmonary edema. The patient should be treated with oxygen and nifedipine with additional 
consideration of sildenafil or tadalafil treatment. Given the patient’s leukocytosis, infiltrates on 
CXR, and fever, it would be reasonable to concurrently treat for pneumonia with antibiotics. 
The patient should be transferred by ground to a hospital with ICU capabilities at lower 
elevation.  
 
Equipment or Props Needed: 
High fidelity simulation mannequin  
Flannel shirt, jeans, and hiking boots to place on the mannequin to signify patient has been 
hiking 
Angiocaths for peripheral intravenous access = 18g, 20g, 22g 
Cardiac monitor 
Pulse oximetry 
IV pole 
Normal saline (1L x2) 
Nasal cannula oxygen 
Non-rebreather mask 
Continuous positive airway pressure (CPAP) or Bilevel positive airway pressure (BiPAP) mask 
Simulated medications with labeling: nifedepine, acetazolamide, sildenafil, dexamethasone 
 
Confederates needed: 
primary nurse 
 
Stimulus Inventory: 
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#1 Complete blood count (CBC) 
#2 Basic metabolic panel (BMP) 
#3 Arterial blood gas (ABG) 
#4 Troponin 
#5 BNP 
#6 D-dimer 
#7 Urinalysis 
#8       hCG qualitative 
#9 Electrocardiogram (ECG) 
#10 Chest Radiograph (CXR) 
#11     Computed tomography pulmonary embolism (CT PE) study 
 
Background and brief information:  Search and rescue were called by the patient’s friend for 
shortness of breath. They brought the patient to the ED after a ground evacuation from a 
backpacking camp 8 miles from the nearest paved road.  
 
Initial presentation: The patient is a 27-year-old female with no past medical history who 
presents from the wilderness via EMS with severe dyspnea. 
 
She reports shortness of breath and chest tightness. She is occasionally coughing. Her cough is 
productive of pink frothy sputum. 
 
She is too dyspneic to converse in full sentences. She denies headache, ataxia or vomiting. She 
endorses nausea. Last meal was 12 hours ago. Her friends tried to feed her in camp, but she 
was too nauseous and dyspneic to eat. She hiked 8 miles today and drank 2 liters of water.  
 
If asked, she lives in Ohio (sea level) and flew to Colorado 2 days ago for a backpacking trip 
with friends. She hiked from 8,000 feet of elevation to 12,000 feet of elevation today. She 
noticed some initial exercise intolerance that worsened as she continued to hike.  
 
The nurse may share that the hospital is a critical access hospital at 11,000 ft. It has an 
emergency room and 25 medical beds. There is not an inpatient critical care unit. 
• Past medical history: none 
• Past surgical history: appendectomy at age 12 
• Medications: combined estrogen/progesterone oral contraceptive pill (OCP) 
• Allergies: none 
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• Family history: noncontributory.  
• Weight: 60 kg 
Assessment: Lying supine, extremely tachypneic with little ability to converse, appears to be 
cyanotic and somewhat drowsy, occasionally coughing 
 
How the scenario unfolds: Patient is a 27-year-old healthy female hiker who presents from the 
wilderness with dyspnea. Per EMS, the patient was backpacking in the Rocky Mountains with 
friends. Throughout the day, she was having increasing trouble keeping up and appeared to be 
mildly short of breath. The shortness of breath worsened and did not resolve with rest, despite 
more frequent breaks to rest and a slower pace. When she did not improve while resting in 
camp, her friends hiked down into town to call for rescue. She was evacuated in a litter by a 
search and rescue team. She is currently too dyspneic to converse in full sentences. 
Participants should obtain an oxygen saturation (O2 sat), temperature, ECG, ABG, chest x-ray, 
and blood work. Diagnostics will reveal a respiratory alkalosis with low PaO2, hypoxia, an 
elevated WBC, and pulmonary edema. The patient should be treated with oxygen and 
nifedipine with consideration for use of sildenafil or tadalafil. Given the patient’s elevated 
WBC, infiltrates on CXR and fever, it would be reasonable to concurrently treat for pneumonia 
with antibiotics. Patient’s tachypnea, tachycardia, and hypoxia improve with oxygenation with 
a modest improvement with the addition of nifedipine. If providers do not apply supplemental 
oxygen, the patient will become progressively more somnolent and bradycardic until pulseless 
electrical activity (PEA) arrest. Return of spontaneous circulation (ROSC) will be achieved once 
patient is appropriately ventilated with a bag-valve mask or intubated. When the transfer 
center is contacted, they should offer admission to an ICU several minutes away at the same 
altitude or a hospital that is an hour away by ground and is 3000 feet lower in elevation. If the 
nearby hospital is chosen, the transfer center will call back in 3 minutes and will state they are 
currently on diversion. The patient should be evacuated by ground to a hospital with ICU 
capabilities at lower elevation.  
 
Critical actions:  
1. Place patient on monitor and obtain a full set of vitals, including temperature and pulse 
oximetry 
2. Apply supplemental oxygen 
3. Obtain IV access 
4. Obtain further history, including current altitude and patient’s rate of ascent  
5. Obtain an ABG, labs, CXR, and ECG 
6. Identify pulmonary edema on CXR 
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7. Treat with nifedipine or a PDE-5 inhibitor 
8. Cover for possible pneumonia with antibiotic therapy 
9. Arrange for transport to a hospital at lower elevation with critical care capabilities   
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Case Title: High Altitude Pulmonary Edema 
 
Chief Complaint: Patient is a 27-year-old female who presents from the wilderness by EMS for 
severe dyspnea 
 
Vitals: Heart Rate (HR) 120 Blood Pressure (BP) 110/76 Respiratory Rate (RR) 36 
 Temperature (T) 100.9°F  Oxygen Saturation (O2Sat) 73% on room air 
 Weight (Wt) 60 kg 
 
General Appearance: lying supine in bed, visibly short of breath with labored respirations, 
cyanotic, having difficulty conversing secondary to dyspnea, drowsy 
 
Primary Survey:  
• Airway: intact 
• Breathing: diffuse rales, severely tachypneic, accessory muscle use present, perioral 
cyanosis 
• Circulation: tachycardic rate and regular rhythm. 2+ symmetric pulses. Cyanosis present 
to distal fingers and to toes. 
 
History:  
• History of present illness: Patient is a 27-year-old female with no previous medical 
history (PMH) who presents from the wilderness via EMS with severe dyspnea and 
reported hallucinations without other signs of altered mental status. 
 
She is too dyspneic to converse in full sentences. She denies headache, ataxia or 
vomiting. She endorses nausea. Last meal was 12 hours ago. Her friends tried to feed 
her in camp, but she was too nauseous to eat. She hiked 8 miles today and drank 2 L of 
water. 
 
If asked, she lives in Ohio (sea level) and flew to Colorado 2 days ago for a backpacking 
trip with friends. She hiked from 8000 ft of elevation to 12,000 ft of elevation today.  
 
The nurse may share that the hospital is a critical access hospital at 11,000 ft. It has an 
emergency room and 25 floor-level beds.  
• Past medical history: none 
• Past surgical history: appendectomy at age 12 
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• Medications: combined estrogen/progesterone OCP 
• Allergies: none 
• Social history:  social drinker, had 2 beers last night. No other alcohol this week. Denies 
drug use. Not currently sexually active. 
• Family history: noncontributory 
 
Secondary Survey/Physical Examination:  
• General appearance: Lying in bed, severely tachypneic with difficulty speaking, appears 
cyanotic, drowsy 
• HEENT:  
o Head: within normal limits other than perioral cyanosis 
o Eyes: within normal limits 
o Ears: within normal limits 
o Nose: within normal limits 
o Throat: within normal limits  
• Neck:  within normal limits 
• Heart: tachycardic, otherwise, within normal limits 
• Lungs: diffuse rales in all lung fields, very tachypneic at rest, using accessory muscles to 
breathe 
• Abdominal/GI: within normal limits 
• Genitourinary: within normal limits 
• Rectal: within normal limits 
• Extremities: Cyanosis present to distal fingers and to toes. 
• Back: within normal limits 
• Neuro: Drowsy but awake and oriented x3. No focal motor or sensory deficits. 
Coordinated in all extremities, if tested. No clonus. Cranial nerves intact. GCS 15 
(E4V5M6). 
• Skin: within normal limits other than cyanosis as noted above 
• Lymph: within normal limits 
• Psych: within normal limits   
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Results:  
Complete blood count (CBC) 
White blood count (WBC)   16.0 x1000/mm3 
Hemoglobin (Hgb)    14.5 g/dL 
Hematocrit (HCT)    45.0% 
Platelet (Plt)     270 x1000/mm3  
 
Basic metabolic panel (BMP) 
Sodium      135 mEq/L 
Chloride       100 mEq/L 
Potassium     4.2 mEq/L 
Bicarbonate (HCO3)   23 mEq/L  
Blood Urea Nitrogen (BUN)  19 mg/dL   
Creatine (Cr)     1.0 mg/dL  
Glucose      85 mg/dL 
Calcium     8.6 mg/dL 
 
Arterial blood gas (ABG) 
pH      7.55 
pCO2      15 mmHg 
pO2      39 mmHg 
HCO3      22 mEq/L 
O2 saturation    73% on room air 
Lactic acid     1.2 mmol/L 
 
Troponin      <0.015 ng/mL 
 
NT-pro BNP      110 pg/mL 
 
D-dimer      <0.1 ug/mL 
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Urinalysis (UA) 
Leukocyte esterase    negative 
Nitrites     negative 
Blood      none 
Protein     none 
Ketones     none 
Glucose     none 
Color      dark yellow 
White blood cells (WBC)   0-5 WBCs/high powered field (HPF) 
Red blood cells (RBC)   0-5 RBCs/HPF 
Squamous epithelial cells  0-5 cells/HPF 
Specific gravity    1.015 
 
hCG qualitative    negative 
 
Electrocardiogram (EKG) 
Heilman, J. Sinus tachycardia as seen on ECG. In: Wikimedia Commons. 
https://commons.wikimedia.org/wiki/File:Sinustachy.JPG. Published June 15, 2012. CC BY-SA 
3.0. 
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Chest Radiograph (CXR) 
Jones, Jeremy. AP portable CXR of a patient in acute pulmonary edema. In: Wikimedia 
Commons. https://commons.wikimedia.org/w/index.php?curid=7371914. Published July 23, 
2009. CC BY-SA 3.0. ros. 
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Computed Tomography Pulmonary Embolism Study 
Hellerhoff. Pulmonary edema in CT-scan coronal MPR. 
https://commons.wikimedia.org/wiki/File:18-01-Lungenoedem_CT_coronar.png. In: 
Wikimedia Commons. Published December 5, 2010. CC BY-SA 3.0. ros. 
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SIMULATION EVENTS TABLE: 
Minute (state) Participant action/ trigger 
Patient status (simulator response) & operator 
prompts 
Monitor display 
(vital signs) 
0:00 
(Baseline) 
Patient moved 
into bed in the 
emergency 
department. 
Participants should begin by placing the patient on 
a monitor, obtaining a history and performing a 
physical exam. 
 
No vitals should 
be displayed 
until requested 
 
T 100.9 
HR 120 
BP 110/76 
RR 36 
O2 73% RA 
04:00 
IV placed, labs 
drawn. 
Participant should 
apply 
supplemental 
oxygen, perform a 
thorough physical 
exam, obtain ECG, 
order labs and 
CXR. 
If the team administers oxygen, tachypnea and O2 
saturation will improve. 
 
If the team does not administer oxygen, patient 
will become obtunded, further desaturate and will 
begin to have a drop in respiratory rate.  
 
If team intubates successfully on first attempt, 
hypoxia will improve to 92%. 
 
If team has difficulty intubating (more than 2 
attempts or a prolonged attempt), go straight to 
PEA arrest (15:00 vitals). 
On a non-
rebreathing 
mask: 
T 100.9 F 
HR 110 
BP 110/76 
RR 35 
O2 86% on 15L 
O2 
 
On a positive 
pressure mask: 
T 100.9 F 
HR 110 
BP 110/76 
RR 30 
O2 90% on BiPAP 
or CPAP 
 
Intubated: 
T 100.9F 
HR 90 
RR (set by team) 
- bagged 
O2 92% bag 
valve mask 
(BVM) 
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Minute (state) Participant action/ trigger 
Patient status (simulator response) & operator 
prompts 
Monitor display 
(vital signs) 
Without oxygen: 
T 100.9F 
HR 130 
BP 90/60 
RR 26 
O2 65% on RA 
10:00 
Administer 
nifedipine and 
oxygen. 
 
If team administers nifedipine to the non-
intubated patient, RR decreases to 26 and 
oxygenation improves to 92%. It not, vitals remain 
unchanged from previous step. 
 
If team administers nifedipine to the non-
intubated patient, oxygenation improves to 94%. 
It not, vitals remain unchanged from previous 
step. 
 
If oxygen is still not administered regardless if 
nifedipine is given, patient’s respiratory rate will 
slow as the patient decompensates (from 8:00-
10:00). After two more minutes (10:00), the 
patient will go into PEA cardiac arrest secondary to 
respiratory arrest for two rounds of appropriately 
performed ACLS until ROSC is achieved. 
Nifedipine given 
with oxygen: 
T 100.9 F 
HR 100 
BP 110/76 
RR 24 
O2 92% on 15L 
O2 or positive 
pressure oxygen 
 
Intubated with 
nifedipine: 
T 100.9F 
HR 90 
RR (set by team) 
- bagged 
O2 94% BVM  
 
Without oxygen: 
T 100.9F 
HR 70 
BP 90/60 
RR 16 
O2 60% on RA 
15:00 (A)  
PEA 
arrest/ROSC 
If patient arrests, 
ROSC will be 
achieved with 2 
rounds of 
appropriate ACLS, 
as long as 
appropriate bag-
valve mask 
respirations or 
Once ICU is contacted, they will ask why the 
patient arrested. They may provide further 
treatment guidance as felt appropriate per 
facilitator. 
 
 
When the transfer center is contacted, they 
should offer admission to an ICU several minutes 
away at the same altitude or a hospital that is an 
During arrest: 
T 100.9F 
HR 70 (PEA) 
RR (set by team) 
- bagged 
O2 86% BVM 
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Minute (state) Participant action/ trigger 
Patient status (simulator response) & operator 
prompts 
Monitor display 
(vital signs) 
airway secured. 
OSH hospital at 
lower elevation 
should be 
contacted for 
direct admission 
to ICU and 
transport 
arranged. 
hour away by ground and is 3000 feet lower in 
elevation.  
 
If the nearby hospital is chosen, the transfer 
center will call back in 3 minutes and will state 
they are currently on diversion. 
Post arrest: 
T 100.9F 
HR 90 
RR (set by team) 
- bagged 
O2 92% BVM 
 
15:00 (B) 
ICU should be 
called for 
admission 
Team contacts 
OSH at lower 
elevation for ICU 
admission and 
arranges for 
transport. 
Case ends. 
 
When the transfer center is contacted, they 
should offer admission to an ICU several minutes 
away at the same altitude or a hospital that is an 
hour away by ground and is 3000 feet lower in 
elevation.  
 
If the nearby hospital is chosen, the transfer 
center will call back in 3 minutes and will state 
they are currently on diversion. 
Oxygen given, no 
nifedipine given: 
T 100.9 F 
HR 110 
BP 110/76 
RR 30 
O2 86% on 15L 
O2 (90% on 
BiPAP/CPAP 
 
Oxygen and 
Nifedipine given: 
T 100.9 F 
HR 100 
BP 110/76 
RR 26 
O2 92% on 15L 
O2 (also 92% on 
BiPAP/CPAP) 
 
Intubated with 
nifedipine: 
T 100.9F 
HR 90 
RR (set by team) 
- bagged 
O2 94% BVM 
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Minute (state) Participant action/ trigger 
Patient status (simulator response) & operator 
prompts 
Monitor display 
(vital signs) 
Intubated 
without 
nifedipine: 
T 100.9F 
HR 90 
RR (set by team) 
- bagged 
O2 92% BVM 
 
 
Diagnosis:  
High Altitude Pulmonary Edema 
 
Disposition:  
Transfer to a hospital at lower elevation (descent required), then ICU
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High Altitude Pulmonary Edema 
Pearls:  
The spectrum of altitude sickness includes acute mountain sickness (AMS), high altitude 
cerebral edema (HACE) and high-altitude pulmonary edema (HAPE). HAPE is the least common 
manifestation of altitude sickness but has the highest fatality without descent.  
 
The incidence of HAPE is less than 1% in the general mountaineering population of the Alps, 
but rises to 10% when non-susceptible individuals ascend to 4559 meters (m) in 24 hours and 
to 60% in susceptible individuals.1 In patients whose partial pressure of oxygen can be rapidly 
reduced to sea-level, there is generally rapid and complete recovery. However, the fatality 
rate was estimated at 50% in hikers in the Himalayas for whom descent was not possible and 
oxygen was not available.1  
 
High altitude pulmonary edema is a clinical diagnosis; however, the Lake Louis Consensus 
Criteria are international guidelines for the diagnosis of HAPE for research purposes. The Lake 
Louis Criteria require at least 2 of the following symptoms: dyspnea at rest, cough, weakness 
or decreased exercise performance, chest tightness or congestion AND 2 of the following 
signs: crackles or wheezing in at least one lung field, central cyanosis, tachypnea, or 
tachycardia. Hemoptysis or pink-frothy sputum are later signs. Neurological symptoms may be 
secondary to hypoxic encephalopathy or a sign of concurrent HACE, which is present in up to 
70% of cases. Patients may have a low-grade fever and universally have hypoxia and 
respiratory alkalosis. Radiologic studies are consistent with pulmonary edema.  
 
High altitude pulmonary edema can be diagnosed based on history and physical, chest x-ray, 
and oxygen saturation alone, but blood work will show a respiratory alkalosis on arterial blood 
gas (ABG) and potentially a mild nonspecific leukocytosis. 
 
The pathophysiology of HAPE is related to induced pulmonary hypertension secondary to 
hypoxemia-driven pulmonary vasoconstriction. Hypoxia occurs secondary to the decreased 
partial pressure of oxygen at high altitude. This pulmonary vasoconstriction causes an alveolar 
capillary leak, resulting in pulmonary edema. 5,6 Certain individuals are more susceptible to 
HAPE than others, independent of age, gender, or level of fitness. It is hypothesized that these 
individuals may have impaired pulmonary nitric oxide synthesis, resulting in an exaggerated 
pulmonary hypertensive response. Individuals susceptible to HAPE are also more likely to have 
impaired alveolar fluid reabsorption due to impaired epithelial sodium transport. 
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High altitude pulmonary edema may present similarly to pneumonia with cough, dyspnea, a 
low-grade fever and a mild leukocytosis. Pneumonia should remain in the differential, but a 
history of high-altitude exposure makes HAPE more likely.  
 
The first-line treatment for HAPE is immediate descent of at least 1000 m in altitude, with 
minimal exertion on the part of the patient, if possible.7 In mild cases, this may be sufficient 
for relief of symptoms. Because exercise can exacerbate symptoms, the patient may need 
assistance in descent. Upon arrival to a hospital, the patient should be treated with 
supplemental oxygen. If oxygen is available prior to descent or descent is not possible, oxygen 
should be applied with goal SpO2 >90%.7 Oxygen and descent are the mainstays of treatment 
of HAPE. Pharmacologic treatments should be considered in patients who are unable to 
achieve an SpO2 >90% with oxygen alone or who are unable to immediately descend. 
Continuous positive airway pressure can be considered when available if the patient is unable 
to maintain oxygen saturation over 90% with supplemental oxygen alone.7 
 
Nifedipine is currently the first-line pharmacologic treatment for HAPE (20 mg extended 
release every 8 hours or 30 mg extended release every 12 hours).7,8 Initial studies of PDE 
inhibitors sildenafil and tadalafil for the treatment and prevention of HAPE show good results 
with less systemic blood pressure reduction compared to nifedipine.3,4 
 
When descent is not possible, administer oxygen and nifedipine, and consider a portable 
hyperbaric chamber (such as Gamow® or Certec® Bags).7,8 There is a risk of recurrence of 
symptoms on emergence from hyperbaric therapy.  
 
Graded ascent and acclimatization are key to prevention of HAPE.7 There is no consensus on 
the recommended rate of ascent, but one source suggests that anyone with a history of HAPE 
should limit ascent to no more than 1155 ft (350 meters) a day.2 Other aspects of prevention 
include avoidance of alcohol, sleep aids, strenuous exercise, and low sleeping altitude. 2 
Prophylaxis is only recommended for those with a history of HAPE. Nifedipine extended 
release 20 mg every 8 hours or 30 mg every 12 hours has been shown to be effective in these 
patients.7,8 Salmeterol 125 mcg inhaled twice daily has also been shown to be effective 
prophylaxis in HAPE-susceptible individuals.8 Studies on the efficacy of sildenafil and tadalafil 
for HAPE prevention are on-going, but initial results show they are superior to placebo.3,4 
There is currently no evidence to support the use of dexamethasone in the treatment of HAPE; 
however, there is a high rate of concurrence of HACE with HAPE. If patients have 
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encephalopathy, they may have hypoxia-induced encephalopathy versus concurrent HACE, 
and it would be reasonable to consider treating with dexamethasone. 
 
Acute mountain sickness (AMS) is characterized by headache and at least one of the following: 
dizziness or lightheadedness, fatigue or weakness, nausea/vomiting/anorexia, insomnia (Lake 
Louis Criteria). Risk factors for AMS include history of AMS in the past, rapid or high ascent, 
and obesity. It is common and does not mandate descent unless symptoms progress to HACE 
or HAPE, but the patient should rest and/or slow the rate of ascent.  
 
High altitude cerebral edema represents the progression of AMS to include the development 
of cerebral edema. It is defined by the symptoms of AMS with additional symptoms of ataxia, 
altered level of consciousness, and/or severe drowsiness. Symptoms can progress to coma. 
The first-line treatment of HACE is immediate descent. HACE can be treated with 
dexamethasone (8 mg once, then 4 mg every 6 hours),7 acetazolamide (as an adjunctive 
therapy, at the AMS treatment dose, below), supplemental oxygen and hyperbarics (if descent 
is not possible). 
 
Acetazolamide is the gold standard for AMS prophylaxis. Acetazolamide 125 mg oral twice 
daily starting 1-2 days prior to ascent is well-studied prophylaxis for AMS/HACE.7 It does not 
have a role in prophylaxis for HAPE. Acetazolamide can also be used at a higher dose (250 mg 
oral twice daily) for the treatment of AMS.7 
 
This case is designed for the learners to include consideration of descent as the patient’s 
disposition because this is a key take-away in the management of altitude illness. Because the 
patient is hypoxic to the 70’s and does not fully respond to oxygen therapy alone, ICU is the 
appropriate final disposition. However, in practice, these patients can rapidly improve with 
descent and oxygen to the extent that they can potentially be admitted to a medical-surgical 
level of care or even discharged home from the emergency room after several hours of 
treatment and monitoring (possibly with oxygen upon discharge) and clear instructions to rest 
and that they are not to re-ascend. 
 
Other debriefing points:  
Closed-loop communication amongst team: was it used? Why or why not? Were there any 
implications of this during case execution? 
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Assessment Timeline 
This timeline is to help observers assess their learners. It allows observer to make notes on when learners 
performed various tasks, which can help guide debriefing discussion. 
 
Critical Actions: 
1. Place patient on monitor and obtain a 
full set of vitals, including temperature 
and pulse oximetry 
2. Apply supplemental oxygen 
3. Obtain IV access 
4. Obtain further history, including 
current altitude and patient’s rate of 
ascent  
5. Obtain an ABG, labs, CXR, and ECG 
6. Identify pulmonary edema on CXR 
7. Treat with nifedipine or an PDE-5 
inhibitor 
8. Cover for possible pneumonia with 
antibiotic therapy 
9. Arrange for transport to a hospital at 
lower elevation with critical care 
capabilities   
 
 
 
 
 
 
 
 
0:00 
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Critical Actions: 
  Place patient on monitor and obtain full set of vitals, including temperature and O2 
saturation 
 Apply supplemental oxygen  
 Obtain IV access 
 Obtain further history, including current altitude and patient’s rate of ascent  
 Check an ABG, labs, CXR, ECG 
 Identify pulmonary edema on CXR 
 Treat with nifedipine or PDE-5 inhibitor 
 Cover for possible pneumonia with antibiotic therapy 
 Arrange for transport to a hospital at lower elevation with critical care capabilities   
 
 
 
 
Summative and formative comments:  
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Milestones assessment: 
 Milestone Did not 
achieve 
level 1 
Level 1 Level 2 Level 3 
 
1 
 
Emergency 
Stabilization (PC1) 
 
 
Did not achieve 
Level 1 
 
 
Recognizes abnormal vital 
signs 
 
 
Recognizes an unstable patient, 
requiring intervention 
 
Performs primary assessment 
 
Discerns data to formulate a 
diagnostic impression/plan 
 
 
 
Manages and prioritizes 
critical actions in a critically ill 
patient 
 
Reassesses after implementing 
a stabilizing intervention 
 
2 
 
Performance of 
focused history and 
physical (PC2) 
 
 
Did not achieve 
Level 1 
 
 
Performs a reliable, 
comprehensive history 
and physical exam 
 
 
Performs and communicates a 
focused history and physical 
exam based on chief complaint 
and urgent issues 
 
 
Prioritizes essential 
components of history and 
physical exam given dynamic 
circumstances 
 
3 
 
Diagnostic studies 
(PC3) 
 
 
Did not achieve 
Level 1 
 
 
Determines the necessity 
of diagnostic studies 
 
 
Orders appropriate diagnostic 
studies. 
 
Performs appropriate bedside 
diagnostic studies/procedures 
 
 
 
Prioritizes essential testing 
 
Interprets results of diagnostic 
studies 
 
Reviews risks, benefits, 
contraindications, and 
alternatives to a diagnostic 
study or procedure 
 
 
4 
 
Diagnosis (PC4) 
 
 
Did not achieve 
Level 1 
 
 
Considers a list of 
potential diagnoses 
 
 
Considers an appropriate list of 
potential diagnosis 
 
May or may not make correct 
diagnosis 
 
 
Makes the appropriate 
diagnosis 
 
Considers other potential 
diagnoses, avoiding premature 
closure 
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 Milestone Did not 
achieve 
level 1 
Level 1 Level 2 Level 3 
 
5 
 
Pharmacotherapy 
(PC5) 
 
 
 
Did not achieve 
Level 1 
 
 
Asks patient for drug 
allergies 
 
 
 
Selects an medication for 
therapeutic intervention, 
consider potential adverse 
effects 
 
 
Selects the most appropriate 
medication and understands 
mechanism of action, effect, 
and potential side effects 
 
Considers and recognizes 
drug-drug interactions 
 
 
6 
 
Observation and 
reassessment (PC6) 
 
 
 
Did not achieve 
Level 1 
 
 
Reevaluates patient at 
least one time during case 
 
 
Reevaluates patient after most 
therapeutic interventions 
 
 
Consistently evaluates the 
effectiveness of therapies at 
appropriate intervals 
 
7 
 
Disposition (PC7) 
 
 
 
Did not achieve 
Level 1 
 
 
Appropriately selects 
whether to admit or 
discharge the patient 
 
 
Appropriately selects whether to 
admit or discharge 
 
Involves the expertise of some of 
the appropriate specialists 
 
 
Educates the patient 
appropriately about their 
disposition 
 
Assigns patient to an 
appropriate level of care 
(ICU/Tele/Floor) 
 
Involves expertise of all 
appropriate specialists 
 
9 
 
General Approach to 
Procedures (PC9) 
 
 
Did not achieve 
Level 1 
 
 
Identifies pertinent 
anatomy and physiology 
for a procedure 
 
Uses appropriate 
Universal Precautions 
 
 
Obtains informed consent  
Knows indications, 
contraindications, anatomic 
landmarks, equipment, 
anesthetic and procedural 
technique, and potential 
complications for common ED 
procedures 
 
 
Determines a back-up strategy 
if initial attempts are 
unsuccessful 
 
Correctly interprets results of 
diagnostic procedure 
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 Milestone Did not 
achieve 
level 1 
Level 1 Level 2 Level 3 
 
20 
 
Professional Values 
(PROF1) 
 
 
Did not achieve 
Level 1 
 
 
Demonstrates caring, 
honest behavior 
 
 
Exhibits compassion, respect, 
sensitivity and responsiveness 
 
 
Develops alternative care 
plans when patients’ personal 
beliefs and decisions preclude 
standard care 
 
22 
 
Patient centered 
communication (ICS1) 
 
 
 
Did not achieve 
level 1 
 
 
Establishes rapport and 
demonstrates empathy to 
patient (and family) 
Listens effectively 
 
 
Elicits patient’s reason for 
seeking health care 
 
 
Manages patient expectations 
in a manner that minimizes 
potential for stress, conflict, 
and misunderstanding. 
 
Effectively communicates with 
vulnerable populations, (at 
risk patients and families) 
 
23 
 
Team management 
(ICS2) 
 
 
 
Did not achieve 
level 1 
 
 
Recognizes other 
members of the patient 
care team during case 
(nurse, techs) 
 
 
Communicates pertinent 
information to other healthcare 
colleagues 
 
 
Communicates a clear, 
succinct, and appropriate 
handoff with specialists and 
other colleagues 
 
Communicates effectively with 
ancillary staff 
 
